Clinical trials: Breast Imaging, active
Neuro-Oncology, MRI Imaging
Mechanistic Study of SPARC-Mediated Regulation of Neutrophil Extracellular Trap Formation in the Brain Metastatic Microenvironment of Breast Cancer
The objective of this observational study is to investigate the characteristics of the tumor microenvironment in patients with brain tumors using multi-modal magnetic resonance imaging (MRI).
- Conditions
- Neuro-Oncology, MRI Imaging, Tumor Immune Microenvironment
- Trial name
- NCT07185646
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Second Xiangya Hospital of Central South University
Head and Neck Cancer, Breast Cancer
Evaluation of Improved Onboard Patient Imaging
The primary objective of radiation therapy is to deliver a therapeutic dose of radiation precisely to the target while minimizing exposure to healthy surrounding tissues.
- Conditions
- Head and Neck Cancer, Breast Cancer, Upper Gastrointestinal Cancer, Lung Cancer
- Trial name
- NCT06187103
- Testing
- HyperSight Imaging
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Varian, a Siemens Healthineers Company
Breast Cancer
Clinical Effectiveness of CEM in Diagnosis of Additional Findings at Preoperative Breast Magnetic Resonance Imaging
In order to explain the value of adding CESM into the clinical pathway, and also to obtain the relevant clinical data to support future update of clinical guideline, we plan to evaluate the detection rate of CESM for additional…
- Trial name
- COMBO-I (NCT06475066)
- Testing
- contrast-enhanced spectral mammography
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Metastatic Urothelial Carcinoma, Breast Cancer
Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.
- Conditions
- Metastatic Urothelial Carcinoma, Breast Cancer, TNBC - Triple-Negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
- Trial name
- NCT07671092
- Testing
- RYZ211/212
- Where
- 6 sites in Australia, New Zealand and 1 more
- Volunteers
- 40 people
- Sponsor
- RayzeBio, Inc.
Breast Cancer
Non-inferiority Study of Contrast-enhanced Digital Mammography (CEDM) vs Magnetic Resonance Imaging (MRI) in Terms of Diagnostic Accuracy in Patients Undergoing Preoperative Staging of Established Invasive Breast Cancer
The general objective of the study is to verify the diagnostic accuracy of contrast-enhanced mammography (CEM) compared to breast magnetic resonance imaging in patients undergoing preoperative staging for breast neoformations…
- Trial name
- CEDM-VR (NCT07071272)
- Testing
- breast-MRI and CEM
- Where
- Italy
- Volunteers
- 216 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Healthy Tissue, Muscles
Deep Optical Imaging of Tissue (DOIT)
In medical imaging, X-ray-based methods are widely used, which means that patients are exposed to ionizing radiation. In addition, invasive tissue samples often need to be taken with biopsy needles to, for example, safely…
- Conditions
- Healthy Tissue, Muscles, Extremity, Breast
- Trial name
- DOIT (NCT07754500)
- Testing
- Mk1
- Where
- Sweden
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Lund University
HER2 Positive Breast Carcinoma, Stage IIIA Breast Cancer
Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer
This phase II trial studies how well copper Cu64-DOTA-trastuzumab positron emission tomography (PET) works in predicting response to treatment with trastuzumab and pertuzumab before surgery in patients with human epidermal growth…
- Conditions
- HER2 Positive Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT02827877
- Testing
- Copper Cu 64-DOTA-Trastuzumab, Laboratory Biomarker Analysis, Pertuzumab
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Breast Cancer
Evaluation of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT for Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in HER2 Positive Early Breast Cancer
The GATHER trial aim to evaluate the diagnostic performance of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT in predicting pCR following neoadjuvant chemotherapy.
- Trial name
- GATHER (NCT07593976)
- Testing
- [68Ga]Ga-NOTA-anti-HER2-sdAb Positron Emission Tomography
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Centre Henri Becquerel
Breast Cancer, Kidney Neoplasms
Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging
This is a 4-arm, single-center study involving 40 participants. Ten healthy volunteers will be enrolled for system imaging optimization, and thirty (30) patients with previously identified lesions in the breast, liver, or…
- Conditions
- Breast Cancer, Kidney Neoplasms, Liver Neoplasms
- Trial name
- NCT07225114
- Testing
- contrast agent perflutren lipid, Ultrasound Imaging
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
ERα+ Breast Cancer, ESR1 Gene Mutation
FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
Despite broad advancements in endocrine therapy for ERα+ breast cancer, resistance ultimately develops. A common driver of resistance are known ESR1 mutations that lead to constitutively active receptor signaling and…
- Trial name
- NCT04174352
- Testing
- Tamoxifen, FES PET/CT
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Wisconsin, Madison
Breast Cancer
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
The purpose of this study is to find out whether pre-operative mpMRI using additional MRI sequences may improve surgical outcomes by providing more accurate information about the extent and acidity of the tumor than standard MRI…
- Trial name
- NCT05130801
- Testing
- pHLIP® ICG NIRF imaging
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma (Skin Cancer), Hepatocellular Carcinoma
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
This prospective, single-center, open-label exploratory diagnostic study aims to evaluate the safety, feasibility, and diagnostic performance of the novel Sortilin-targeted PET tracer 68Ga-SorB in patients with solid tumors.
- Conditions
- Melanoma (Skin Cancer), Hepatocellular Carcinoma, Lung Cancer, Breast Cancer
- Trial name
- SORB-PET (NCT07760012)
- Testing
- 68Ga-SorB PET/CT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Third Hospital
Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of [68Ga]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC)…
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Urothelial Carcinoma (UC)
- Trial name
- NCT05706129
- Testing
- [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452
- Where
- 10 sites in Australia, France
- Volunteers
- 270 people
- Sponsor
- Lumara Bio Oncologics GmbH
Breast Cancer With Low to Intermediate HER2 Expression
Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer
The purpose of this study is to determine whether a personalized, risk-stratified surveillance strategy can safely reduce unnecessary cardiac imaging while preserving early detection of treatment-related cardiotoxicity in women…
- Trial name
- POCEB (NCT07630402)
- Testing
- Echocardiogram
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Rochester
Breast Neoplasms, Artificial Intelligence (AI)
Non-Contrast Breast MRI Diagnosis and Risk Stratification Using DWI-Generated Synthetic Contrast Enhancement
This study is conducted under the ethics-approved project titled "Artificial Intelligence Solution for Simplifying the Diagnostic Workflow of Breast MRI''.The goal of this observational study is to develop an integrated breast…
- Conditions
- Breast Neoplasms, Artificial Intelligence (AI), Magnetic Resonance Imaging (MRI), Diffusion Magnetic Resonance Imaging
- Trial name
- NCT07598084
- Testing
- Non-contrast breast MRI diagnostic model
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Breast Cancer
Clinical Study of 18F-Labeled FAPI-04 in PET Imaging of Breast Cancer
This study aims to evaluate the diagnostic accuracy (sensitivity, specificity, positive/negative predictive value, and overall accuracy) of 18F-FAPI-04 PET imaging in breast cancer for detecting fibroblast activation protein…
- Trial name
- NCT06916338
- Testing
- 18F-FAPI-04 PET scan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Breast Cancer
Accuracy of Sono-mammographic Features in Molecular Classification of Breast Cancer
This study aims to evaluate the role of mammographic and sonographic features as non-invasive imaging tools in predicting the molecular subtypes of breast cancer, in correlation with histopathological findings.
- Trial name
- NCT07354490
- Testing
- Diagnostic test: Ultrasound and Mammogram
- Volunteers
- 122 people
- Sponsor
- Assiut University
Invasive Breast Cancer
Adding Preoperative Radiotherapy Based on Early Treatment Response in Breast Cancer
RAPID-NeoBC is a prospective, multicentre, response-adapted study with a randomized component for adults with operable, nonmetastatic invasive breast cancer receiving guideline-recommended neoadjuvant systemic therapy.
- Trial name
- RAPID-NeoBC (NCT07892508)
- Testing
- Response-adapted preoperative radiotherapy, Guideline-recommended neoadjuvant systemic therapy, Serial contrast-enhanced breast MRI and breast-specific gamma imaging
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer Stage IV, HER2-low Breast Cancer
HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC
This is a prospective, multi-center, open-label, exploratory diagnostic phase II imaging trial for patients with metastatic breast cancer with at least one line of systemic therapy.
- Conditions
- Breast Cancer Stage IV, HER2-low Breast Cancer, Molecular Imaging
- Trial name
- NCT06830382
- Testing
- Positron emission tomografy with [68Ga]Ga-ABY-025
- Where
- Sweden
- Volunteers
- 70 people
- Sponsor
- Renske Altena
Breast Neoplasms、Lung Neoplasms、Pancreatic Neoplasms
68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors
Tumor metastasis and invasion are the leading causes of cancer-related deaths, with over 90% of cancer patients dying from distant metastasis.
- Trial name
- NCT07331532
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking University First Hospital